Last reviewed · How we verify
Delayed-release omeprazole
At a glance
| Generic name | Delayed-release omeprazole |
|---|---|
| Sponsor | University of Louisville |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant (PHASE1)
- A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants (PHASE1)
- Effect of Dexlansoprazole on Bone Homeostasis (PHASE1)
- Bioequivalence Study of Esomeprazole 20 Milligram (mg) Delayed-Release Capsules in Healthy Adult Participants (PHASE1)
- An Drug-drug Interaction Study to Evaluate the Effects of Omeprazole 40mg on the Pharmacokinetics of SPRYCEL® (PHASE1)
- A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults (PHASE1)
- A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults (PHASE1)
- Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Delayed-release omeprazole CI brief — competitive landscape report
- Delayed-release omeprazole updates RSS · CI watch RSS
- University of Louisville portfolio CI